<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JHEP Rep</journal-id><journal-id journal-id-type="iso-abbrev">JHEP Rep</journal-id><journal-title-group><journal-title>JHEP Reports</journal-title></journal-title-group><issn pub-type="epub">2589-5559</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38125301</article-id><article-id pub-id-type="pmc">PMC10733101</article-id><article-id pub-id-type="pii">S2589-5559(23)00285-9</article-id><article-id pub-id-type="doi">10.1016/j.jhepr.2023.100954</article-id><article-id pub-id-type="publisher-id">100954</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Hartl</surname><given-names>Lukas</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Simbrunner</surname><given-names>Benedikt</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Jachs</surname><given-names>Mathias</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Wolf</surname><given-names>Peter</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Bauer</surname><given-names>David Josef Maria</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Scheiner</surname><given-names>Bernhard</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Balcar</surname><given-names>Lorenz</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Semmler</surname><given-names>Georg</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Schwarz</surname><given-names>Michael</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Marculescu</surname><given-names>Rodrig</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Dannenberg</surname><given-names>Varius</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Trauner</surname><given-names>Michael</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Mandorfer</surname><given-names>Mattias</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au14"><name><surname>Reiberger</surname><given-names>Thomas</given-names></name><email>thomas.reiberger@meduniwien.ac.at</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>1</label>Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria</aff><aff id="aff2"><label>2</label>Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria</aff><aff id="aff3"><label>3</label>Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria</aff><aff id="aff4"><label>4</label>Division of Endocrinology, Department of Medicine III, Medical University of Vienna, Vienna, Austria</aff><aff id="aff5"><label>5</label>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria</aff><aff id="aff6"><label>6</label>Division of Cardiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Address: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Tel.: +4314040065890; Fax: +4314040047350. <email>thomas.reiberger@meduniwien.ac.at</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>01</day><month>11</month><year>2023</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>1</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>01</day><month>11</month><year>2023</year></pub-date><volume>6</volume><issue>1</issue><elocation-id>100954</elocation-id><history><date date-type="received"><day>26</day><month>7</month><year>2023</year></date><date date-type="rev-recd"><day>2</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 The Author(s)</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background &#x00026; Aims</title><p>Advanced chronic liver disease (ACLD) may affect thyroid hormone homeostasis. We aimed to analyze the pituitary&#x02013;thyroid axis in ACLD and the prognostic value of free triiodothyronine (fT3).</p></sec><sec><title>Methods</title><p>Patients with ACLD (liver stiffness measurement [LSM] &#x02265;10&#x000a0;kPa) undergoing hepatic venous pressure gradient (HVPG) measurement between June 2009 and September 2022 and available fT3 levels were included. Clinical stages of ACLD were defined as follows: probable ACLD (pACLD; LSM &#x02265;10&#x000a0;kPa and HVPG &#x02264;5&#x000a0;mmHg), S0 (mild portal hypertension [PH]; HVPG&#x000a0;6&#x02013;9&#x000a0;mmHg), S1 (clinically significant PH), S2 (clinically significant PH with varices), S3 (past variceal bleeding), S4&#x000a0;(past/current non-bleeding hepatic decompensation), and S5 (further decompensation).</p></sec><sec><title>Results</title><p>Among 297 patients with ACLD, 129 were compensated (pACLD, n&#x000a0;= 10; S0, n&#x000a0;= 33; S1, n&#x000a0;= 42; S2, n&#x000a0;= 44), whereas 168 were decompensated (S3, n&#x000a0;= 12; S4, n&#x000a0;= 97; S5, n&#x000a0;= 59). Median levels of thyroid-stimulating hormone (TSH) numerically increased with progressive ACLD stage (from 1.2 &#x003bc;IU/ml [pACLD] to 1.5 &#x003bc;IU/ml [S5]; <italic>p</italic>&#x000a0;= 0.152), whereas fT3 decreased (from 3.2&#x000a0;pg/ml [pACLD] to 2.5&#x000a0;pg/ml [S5]; <italic>p</italic> &#x0003c;0.001). Free thyroxin levels remained unchanged (<italic>p</italic>&#x000a0;= 0.338). TSH (aB 0.45; <italic>p</italic>&#x000a0;= 0.046) and fT3 (aB -0.17; <italic>p</italic>&#x000a0;= 0.048) were independently associated with systemic C-reactive protein levels. Lower fT3 was linked to higher risk of (further) decompensation (adjusted subdistribution hazard ratio [asHR] 0.60; 95% CI 0.37&#x02013;0.97; <italic>p</italic>&#x000a0;= 0.037), acute-on-chronic liver failure (asHR 0.19; 95% CI 0.08&#x02013;0.49; <italic>p</italic> &#x0003c;0.001) and liver-related death (asHR 0.14; 95% CI 0.04&#x02013;0.51; <italic>p</italic>&#x000a0;=&#x000a0;0.003).</p></sec><sec><title>Conclusions</title><p>Increasing TSH and declining fT3 levels are observed with progressive ACLD stages. The association of TSH&#x000a0;and fT3 with systemic inflammation suggests a liver disease-associated non-thyroidal illness syndrome. Lower fT3 levels in patients with ACLD indicate increased risk for decompensation, acute-on-chronic liver failure, and liver-related death.</p></sec><sec><title>Impact and Implications</title><p>In a large well-characterized cohort of patients with advanced chronic liver disease (ACLD), we found a decline of free triiodothyronine (fT3) throughout the clinical stages of ACLD, paralleled by a numerical increase of thyroid-stimulating hormone (TSH). This suggests a progressive development of a non-thyroidal illness syndrome in association with ACLD severity. Importantly, C-reactive protein independently correlated with TSH and fT3, linking thyroid dysbalance in ACLD to systemic inflammation. Lower fT3 indicated an increased risk for subsequent development of hepatic decompensation, acute-on-chronic liver failure, and liver-related death.</p></sec><sec><title>Clinical trial number</title><p>Vienna Cirrhosis Study (VICIS; NCT: <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT03267615" id="intref0010">NCT03267615</ext-link>).</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="ga1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Non-thyroidal illness syndrome is increasingly common with progressive substages of advanced chronic liver disease.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Systemic inflammation is independently linked to fT3 and TSH in advanced chronic liver disease.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">fT3 correlates with parameters of liver dysfunction, portal hypertension, endothelial dysfunction, and hyperdynamic circulation.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Lower fT3 is an independent risk factor for hepatic decompensation, acute-on-chronic liver failure, and liver-related death.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Thyroid</kwd><kwd>TSH</kwd><kwd>Thyroxin</kwd><kwd>Triiodothyronine</kwd><kwd>Inflammation</kwd><kwd>Advanced chronic liver disease</kwd><kwd>Portal hypertension</kwd><kwd>Non-invasive testing</kwd></kwd-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0055">ACLD</term><def><p>advanced chronic liver disease</p></def></def-item><def-item><term id="kwrd0065">ACLF</term><def><p>acute-on-chronic liver failure</p></def></def-item><def-item><term id="kwrd0075">asHR</term><def><p>adjusted sHR</p></def></def-item><def-item><term id="kwrd0085">AIH</term><def><p>autoimmune hepatitis</p></def></def-item><def-item><term id="kwrd0095">ALD</term><def><p>alcohol-related liver disease</p></def></def-item><def-item><term id="kwrd0105">cACLD</term><def><p>compensated ACLD</p></def></def-item><def-item><term id="kwrd0115">CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term id="kwrd0125">CTP</term><def><p>Child&#x02013;Turcotte&#x02013;Pugh</p></def></def-item><def-item><term id="kwrd0135">dACLD</term><def><p>decompensated ACLD</p></def></def-item><def-item><term id="kwrd0145">fT3</term><def><p>free triiodothyronine</p></def></def-item><def-item><term id="kwrd0155">fT4</term><def><p>free thyroxin</p></def></def-item><def-item><term id="kwrd0165">FU</term><def><p>follow-up</p></def></def-item><def-item><term id="kwrd0175">HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term id="kwrd0185">HE</term><def><p>hepatic encephalopathy</p></def></def-item><def-item><term id="kwrd0195">HVPG</term><def><p>hepatic venous pressure gradient</p></def></def-item><def-item><term id="kwrd0205">INR</term><def><p>international normalized ratio</p></def></def-item><def-item><term id="kwrd0215">LLN</term><def><p>lower limit of normal</p></def></def-item><def-item><term id="kwrd0225">LSM</term><def><p>liver stiffness measurement</p></def></def-item><def-item><term id="kwrd0235">LT</term><def><p>liver transplantation</p></def></def-item><def-item><term id="kwrd0245">MAP</term><def><p>mean arterial pressure</p></def></def-item><def-item><term id="kwrd0255">MASH</term><def><p>metabolic dysfunction-associated steatohepatitis</p></def></def-item><def-item><term id="kwrd0265">MELD</term><def><p>model for end-stage liver disease</p></def></def-item><def-item><term id="kwrd0275">pACLD</term><def><p>probable ACLD</p></def></def-item><def-item><term id="kwrd0285">PH</term><def><p>portal hypertension</p></def></def-item><def-item><term id="kwrd0295">proBNP</term><def><p>pro-brain-type natriuretic peptide</p></def></def-item><def-item><term id="kwrd0305">PVT</term><def><p>portal vein thrombosis</p></def></def-item><def-item><term id="kwrd0315">SBP</term><def><p>spontaneous bacterial peritonitis</p></def></def-item><def-item><term id="kwrd0325">sHR</term><def><p>subdistribution hazard ratio</p></def></def-item><def-item><term id="kwrd0335">T3</term><def><p>triiodothyronine</p></def></def-item><def-item><term id="kwrd0345">T4</term><def><p>thyroxin</p></def></def-item><def-item><term id="kwrd0355">TBG</term><def><p>thyroxin-binding globulin</p></def></def-item><def-item><term id="kwrd0365">TIPS</term><def><p>transjugular intrahepatic portosystemic shunt</p></def></def-item><def-item><term id="kwrd0375">TSH</term><def><p>thyroid-stimulating hormone</p></def></def-item><def-item><term id="kwrd0385">ULN</term><def><p>upper limit of normal</p></def></def-item><def-item><term id="kwrd0395">VICIS</term><def><p>Vienna Cirrhosis Study</p></def></def-item><def-item><term id="kwrd0405">VWF</term><def><p>von Willebrand factor antigen</p></def></def-item><def-item><term id="kwrd0415">WBC</term><def><p>white blood cell count</p></def></def-item></def-list></front><body><sec id="sec1"><title>Introduction</title><p id="p0030">Advanced chronic liver disease (ACLD) causes considerable morbidity and mortality worldwide.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> In early asymptomatic stages, ACLD is considered compensated. With the development of portal hypertension (PH)-related complications, including ascites, hepatic encephalopathy (HE), and variceal bleeding, patients progress to decompensated ACLD (dACLD),<xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref> which is associated with a considerably worse prognosis.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> Acute-on-chronic liver failure (ACLF), defined by hepatic and/or extrahepatic organ failure(s),<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> may occur in patients with dACLD<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> and is closely associated with systemic inflammation.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></p><p id="p0035">There is a complex interplay between chronic liver disease and thyroid function. On the one hand, the liver is essentially involved in thyroid hormone homeostasis, contributing to their (in) activation, transport, and metabolism.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> On the other hand, hypothyroidism is known to impair lipid metabolism and promote hepatic steatosis.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Accordingly, the risk of non-alcoholic fatty liver disease (NAFLD) increases with lower free thyroxin (fT4) levels.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Moreover, increased thyroid-stimulating hormone (TSH) was associated with NAFLD in a meta-analysis.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Accordingly, thyroid hormones and thyroid hormone receptor beta agonists are currently evaluated as potential therapies for NAFLD.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></p><p id="p0040">Furthermore, a small study including 33 patients with liver cirrhosis reported lower levels of triiodothyronine (T3) and free T3 (fT3), as well as lower T3/thyroxin-binding globulin (TBG) and thyroxin (T4)/TBG ratios.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> A typical altered pattern of thyroid hormone homeostasis with decreased levels of fT3 and similar levels of fT4 was described in cirrhosis, and defined as &#x02018;low fT3 syndrome&#x02019;.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Moreover, a small retrospective study demonstrated shorter survival among patients with low fT3,<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> linking dysregulated thyroid signaling to impaired clinical outcomes in patients with cirrhosis.</p><p id="p0045">However, abnormalities of the pituitary&#x02013;thyroid axis across the distinct substages of cirrhosis, as well as the impact of fT3 on different clinical outcomes, have not yet been systematically investigated. Thus, this study aimed (i) to investigate the pituitary&#x02013;thyroid axis throughout the individual clinical stages of ACLD,<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> (ii) to analyze parameters associated with the dysregulation of thyroid hormones in ACLD, and (iii) to determine the impact of fT3 on clinical outcomes of ACLD.</p></sec><sec id="sec2"><title>Patients and methods</title><sec id="sec2.1"><title>Study design</title><p id="p0050">This study investigated consecutive patients with suspected ACLD (<italic>i.e.</italic> liver stiffness measurement [LSM] &#x02265;10&#x000a0;kPa) undergoing HVPG measurement at the Hepatic Hemodynamic Lab of the Vienna General Hospital between June 2009 and September 2022 following a standardized operating procedure.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> We exclusively included clinically stable patients in whom data on TSH and fT3 were available.</p><p id="p0055">Patients with a history of liver transplantation (LT), hepatocellular carcinoma (HCC) or other malignancy, vascular liver disease, portal vein thrombosis (PVT), transjugular intrahepatic portosystemic shunt (TIPS), congestive heart disease, intake of thyroid hormones, or active infection at the time of HVPG measurement were excluded. Moreover, we excluded patients with insufficient available clinical or laboratory data.</p><p id="p0060">Central venous blood withdrawals for assessment of pituitary&#x02013;thyroid axis parameters and HVPG measurements were conducted under fasting conditions. Clinical events occurring during follow-up (FU) including the development of decompensation events (clinically apparent ascites, variceal bleeding, HE, and ACLF), as well as acute kidney injury, HCC, LT, and (liver-related) death, were documented.</p></sec><sec id="sec2.2"><title>Patient cohorts</title><p id="p0065">Patients were stratified for ACLD severity according to clinical stages modified from D&#x02019;Amico <italic>et&#x000a0;al.</italic><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> for baseline characterization of the pituitary&#x02013;thyroid axis in patients with ACLD. Compensated ACLD (cACLD) was defined by the absence of any previous decompensating event defined and was further subdivided into four distinct stages: probable ACLD (pACLD; LSM &#x02265;10&#x000a0;kPa and HVPG &#x02264;5&#x000a0;mmHg),<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> S0 (mild PH; HVPG 6&#x02013;9&#x000a0;mmHg), S1 (clinically significant PH [<italic>i.e.</italic> HVPG &#x02265;10&#x000a0;mmHg] without the presence of varices), and S2 (clinically significant PH with the presence of varices). dACLD was constituted by a history of at least one decompensation event. Patients with dACLD were assigned to one of three substages: S3 (history of acute variceal bleeding), S4 (history of decompensation as a result of non-bleeding decompensating events including ascites and HE), and S5 (further decompensation; <italic>i.e.</italic> history of two or more different types of decompensating events).</p></sec><sec id="sec2.3"><title>Decompensation events</title><p id="p0070">In cACLD, decompensation was defined by occurrence of clinically evident ascites, HE, or variceal bleeding. In dACLD, further decompensation was defined by either occurrence of a second type of hepatic decompensation or worsening of the first decompensation. Worsening included development of spontaneous bacterial peritonitis (SBP) or refractory ascites in patients with ascites, first hospital (re-) admission caused by HE in patients with previous HE, and variceal rebleeding in patients with a history of variceal bleeding. Finally, ACLF following the EASL/EF-CLIF definition<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> was regarded as a fourth and distinct type of decompensating event, which could potentially occur in patients with cACLD and those with dACLD.</p></sec><sec id="sec2.4"><title>Assessment of HVPG and LSM</title><p id="p0075">A standardized HVPG measurement procedure was followed as previously described.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> In brief, a catheter introducer sheath was placed in the right internal jugular vein following local anesthesia. Subsequently, a specifically designed angled-tip balloon catheter<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> was inserted into a large hepatic vein under fluoroscopic guidance. HVPG was calculated by subtracting free from wedged hepatic vein pressure. A total of three measurements were performed per patient, and the median HVPG of these measurements was used for further analyses. Vibration-controlled transient elastography (FibroScan&#x000ae;; Echosens, Paris, France) under fasting conditions was used for LSM, as previously described.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></p></sec><sec id="sec2.5"><title>Pituitary&#x02013;thyroid axis parameters and routine laboratory parameters</title><p id="p0080">All laboratory tests were conducted at the ISO-certified Department of Laboratory Medicine of the Vienna General Hospital. Blood withdrawals were conducted in a standardized manner after HVPG measurement under fasting conditions and after resting in the supine position for at least 30&#x000a0;min. Serum levels of TSH (normal range 0.27&#x02013;4.2 &#x003bc;IU/ml; Elecsys TSH, Roche Diagnostics, Mannheim, Germany), as well as fT4 (normal range 0.76&#x02013;1.66&#x000a0;ng/dl; Elecsys fT4 III, Roche Diagnostics, Mannheim, Germany) and fT3 (normal range 2.15&#x02013;4.12&#x000a0;pg/ml; Elecsys fT3 III, Roche Diagnostics) were analyzed by electrochemoluminescence immunoassay (Roche Diagnostics). Standard laboratory methods were used for the assessment of routine laboratory parameters. Low fT4 and low fT3 were defined as fT4 &#x0003c;lower limit of normal (LLN) and fT3 &#x0003c;LLN, respectively. Elevated TSH was defined as TSH &#x0003e;upper limit of normal (ULN).</p></sec><sec id="sec2.6"><title>Statistical analysis</title><p id="p0085">The number (n) and proportion (%) of patients with the parameter of interest were reported for categorical variables. Continuous data were presented using median and IQR. For comparison of continuous non-normally distributed variables between two groups, the Mann&#x02013;Whitney <italic>U</italic> test was implemented. The Kruskal&#x02013;Wallis test was performed for comparing continuous variables in three or more groups. Pearson&#x02019;s Chi-square test or Fisher&#x02019;s exact test, as appropriate, was used for group comparisons of categorical variables. Spearman&#x02019;s rho (&#x003c1;) was used to assess correlations. Linear regression analysis was conducted to investigate factors associated with TSH and fT3. Clinical outcomes at half-year intervals up to 2 years of FU were assessed using cumulative incidence calculation. Gray&#x02019;s test, as previously described,<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> was computed for cumulative incidence comparison. Fine and Gray competing risk regression models using the R package cmprsk<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> were calculated to evaluate whether TSH, fT4, and fT3 levels were associated with the risk of clinical events of interest. Apart from TSH, fT4, and fT3, well-established risk factors for worse outcomes in ACLD (<italic>i.e</italic>. age, Child&#x02013;Turcotte&#x02013;Pugh [CTP] score, serum creatinine, sodium, HVPG as a marker for PH, and C-reactive protein [CRP] as a parameter of systemic inflammation) as well as sex were evaluated by univariate and multivariate analysis. Etiological cure, HCC, LT, and non-liver-related death were considered as competing risks for both cumulative incidence comparisons and competing risk regression models. In both the linear regression models and the competing risk regression models, parameters that were associated with the parameter of interest in univariate analysis (<italic>p</italic> &#x0003c;0.100) were included in the multivariate model. Moreover, TSH, fT3, or fT4 as the main target parameters, as well as BMI, CTP score, and HVPG as established parameters of pathophysiological and prognostic relevance, were included in the multivariate models. IBM SPSS 27.0 statistic software (IBM, Armonk, NY, USA), R 4.2.1 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria), and GraphPad Prism 8 (GraphPad Software, La Jolla, CA, USA) were used for statistical analyses. A two-sided <italic>p</italic> value of &#x0003c;0.05 was considered statistically significant.</p></sec><sec id="sec2.7"><title>Ethics</title><p id="p0090">The study was approved by the ethics committee of the Medical University of Vienna (No. 1493/2016 and No. 1262/2017) and was performed in accordance with the current version of the Helsinki Declaration. All patients included between 2018 and 2022 are part of the prospective Vienna Cirrhosis Study (VICIS; NCT: <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT03267615" id="intref0015">NCT03267615</ext-link>) and gave their written informed consent before study inclusion. The ethics committee waved the need for informed consent for the retrospective part of the study.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Patient characteristics</title><p id="p0095">In total, 297 patients with ACLD with a median age of 56.0 years and male predominance (67.0%) were included in the study. The patient flow chart is depicted in <xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>. Baseline characteristics of the included patients are provided in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. The main etiologies were alcohol-related liver disease (53.9%), viral hepatitis (16.5%), and metabolic dysfunction-associated steatohepatitis (MASH; 11.8%). Overall, the study included 56.6% of patients with dACLD &#x02013; most frequently caused by ascites (85.7% of patients with dACLD). The median HVPG was 17&#x000a0;mmHg, and the median model for end-stage liver disease (MELD) was 11 points.<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>Patient flow chart.</p><p>ACLD, advanced chronic liver disease; fT3, free triiodothyronine; HCC, hepatocellular carcinoma; HVPG, hepatic venous pressure gradient; LSM, liver stiffness measurement; LT, liver transplantation; pACLD, probable ACLD (<italic>i.e.</italic> LSM &#x02265;10&#x000a0;kPa and HVPG &#x02264;5&#x000a0;mmHg); PVT, portal vein thrombosis; TIPS, transjugular intrahepatic portosystemic shunt; TSH, thyroid-stimulating hormone.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient characteristics</th><th>All patients (N&#x000a0;= 297)</th></tr></thead><tbody><tr><td>Sex, male/female (% male)</td><td>199/98 (67.0)</td></tr><tr><td>Age (years), median (IQR)</td><td>56.0 (48.0&#x02013;63.8)</td></tr><tr><td>BMI (kg/m<sup>2</sup>), median (IQR)<hr/></td><td>26.0 (22.9-29.7)<hr/></td></tr><tr><td colspan="2">Etiology</td></tr><tr><td>ALD, n (%)</td><td>160 (53.9)</td></tr><tr><td>Viral hepatitis, n (%)</td><td>49 (16.5)</td></tr><tr><td>MASH, n (%)</td><td>35 (11.8)</td></tr><tr><td>Cholestatic, n (%)</td><td>21 (7.1)</td></tr><tr><td>AIH, n (%)</td><td>9 (3.0)</td></tr><tr><td>Other, n (%)<hr/></td><td>23 (7.7)<hr/></td></tr><tr><td>Decompensated ACLD, n (%)</td><td>168 (56.6)</td></tr><tr><td>Ascites, n (%)</td><td>144 (48.5)</td></tr><tr><td>Refractory ascites, n (%)</td><td>27 (9.1)</td></tr><tr><td>Hepatic encephalopathy, n (%)</td><td>54 (18.2)</td></tr><tr><td>Variceal bleeding, n (%)<hr/></td><td>35 (11.8)<hr/></td></tr><tr><td colspan="2">EASL stage</td></tr><tr><td>Probable ACLD, n (%)</td><td>10 (3.4)</td></tr><tr><td>0, n (%)</td><td>33 (11.1)</td></tr><tr><td>1, n (%)</td><td>42 (14.1)</td></tr><tr><td>2, n (%)</td><td>44 (14.8)</td></tr><tr><td>3, n (%)</td><td>12 (4.0)</td></tr><tr><td>4, n (%)</td><td>97 (32.7)</td></tr><tr><td>5, n (%)<hr/></td><td>59 (19.9)<hr/></td></tr><tr><td>MELD (points), median (IQR)</td><td>11 (9&#x02013;15)</td></tr><tr><td>CTP score (points), median (IQR)</td><td>6 (5&#x02013;8)</td></tr><tr><td colspan="2">CTP stage</td></tr><tr><td>A, n (%)</td><td>159 (53.5)</td></tr><tr><td>B, n (%)</td><td>102 (34.3)</td></tr><tr><td>C, n (%)</td><td>36 (12.1)</td></tr><tr><td>Bilirubin (mg/dl), median (IQR)</td><td>1.1 (0.7&#x02013;2.3)</td></tr><tr><td>Albumin (g/dl), median (IQR)</td><td>36.9 (32.8&#x02013;40.2)</td></tr><tr><td>INR (U), median (IQR)</td><td>1.4 (1.2&#x02013;1.6)</td></tr><tr><td>Sodium (mmol/L), median (IQR)<hr/></td><td>138.0 (136.0&#x02013;140.5)<hr/></td></tr><tr><td>HVPG (mmHg), median (IQR)</td><td>17 (11&#x02013;20)</td></tr><tr><td>MAP (mmHg), median (IQR)</td><td>99 (90&#x02013;111)</td></tr><tr><td>LSM (kPa), median (IQR)<hr/></td><td>36.5 (22.0&#x02013;61.7)<hr/></td></tr><tr><td>TSH (&#x003bc;IU/ml), median (IQR)</td><td>1.5 (1.1&#x02013;2.2)</td></tr><tr><td>fT3 (pg/ml), median (IQR)</td><td>2.8 (2.4&#x02013;3.2)</td></tr><tr><td>fT4 (ng/dl), median (IQR)<hr/></td><td>1.2 (1.0&#x02013;1.3)<hr/></td></tr><tr><td>IL-6<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref> (ng/dl), median (IQR)</td><td>8.4 (4.7&#x02013;15.7)</td></tr><tr><td>WBC (G/L), median (IQR)</td><td>4.8 (3.5&#x02013;6.3)</td></tr><tr><td>CRP (mg/dl), median (IQR)</td><td>0.2 (0.1&#x02013;0.6)</td></tr></tbody></table><table-wrap-foot><fn><p>ACLD, advanced chronic liver disease; AIH, autoimmune hepatitis; ALD, alcohol-related liver disease; CRP, C-reactive protein; CTP, Child&#x02013;Turcotte&#x02013;Pugh; fT3, free triiodothyronine; fT4, free thyroxin; HVPG, hepatic venous pressure gradient; INR, international normalized ratio; LSM, liver stiffness measurement; MAP, mean arterial pressure; MASH, metabolic dysfunction-associated steatohepatitis; MELD, model for end-stage liver disease; TSH, thyroid-stimulating hormone; WBC, white blood cell count.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnlowast"><label>&#x02217;</label><p id="ntpara0010">Available in 286 patients.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.2"><title>Pituitary&#x02013;thyroid axis parameters in patients with different clinical stages of ACLD</title><p id="p0100">With progressive ACLD severity, patients exhibited numerically higher levels of TSH (from 1.2 &#x003bc;IU/ml [pACLD] to 1.5 &#x003bc;IU/ml [S5]; <italic>p</italic>&#x000a0;= 0.152; <xref rid="fig2" ref-type="fig">Fig.&#x000a0;2</xref> and <xref rid="appsec1" ref-type="sec">Table&#x000a0;S1</xref>). Still, TSH mostly remained within the normal range with only overall nine patients (3.0%; no difference between distinct clinical stages; see <xref rid="appsec1" ref-type="sec">Table&#x000a0;S1</xref>) exhibiting elevated levels. At the same time, median fT3 levels decreased throughout the clinical substages (from 3.2&#x000a0;pg/ml [pACLD] to 2.5&#x000a0;pg/ml [S5]; <italic>p</italic> &#x0003c;0.001), whereas median fT4 remained unchanged (1.2&#x000a0;ng/dl [pACLD] <italic>vs</italic>. 1.2&#x000a0;ng/dl [S5]; <italic>p</italic>&#x000a0;= 0.338). Importantly, 12.8% (n&#x000a0;= 38/297) of patients with ACLD had low (<italic>i.e.</italic> &#x0003c;LLN) fT3 levels with significantly higher prevalence among advanced clinical stages (0.0% [pACLD] <italic>vs</italic>. 27.1% [S5]; <italic>p</italic>&#x000a0;= 0.015). <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref> depicts the levels of parameters of the pituitary&#x02013;thyroid axis in cACLD compared with dACLD.<fig id="fig2"><label>Fig.&#x000a0;2</label><caption><p>Plasma levels of thyroid-stimulating hormone, free thyroxin, free triiodothyronine, and C-reactive protein in patients with different stages of ACLD.</p><p>Statistical differences between the groups were assessed using Kruskal-Wallis test. Patients were stratified by EASL stages with the addition of patients with pACLD (<italic>i.e.</italic> HVPG &#x02264;5&#x000a0;mmHg and LSM &#x02265;10&#x000a0;kPa). HVPG, hepatic venous pressure gradient; LSM, liver stiffness measurement; pACLD, probable advanced chronic liver disease.</p></caption><graphic xlink:href="gr2"/></fig><table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Levels of parameters of the pituitary&#x02013;thyroid axis, liver function, and systemic inflammation in patients with cACLD and dACLD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>cACLD (n&#x000a0;= 129), median (IQR)</th><th>dACLD (n&#x000a0;= 168), median (IQR)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>TSH (&#x003bc;IU/ml)</td><td>1.4 (1.0&#x02013;1.9)</td><td>1.6 (1.1&#x02013;2.4)</td><td>0.012</td></tr><tr><td>fT3 (pg/ml)</td><td>3.0 (2.6&#x02013;3.2)</td><td>2.7 (2.3&#x02013;3.0)</td><td>&#x0003c;0.001</td></tr><tr><td>fT4 (ng/dl)<hr/></td><td>1.1 (1.0&#x02013;1.3)<hr/></td><td>1.2 (1.0&#x02013;1.3)<hr/></td><td>0.006<hr/></td></tr><tr><td>CTP score (points)</td><td>5.0 (5.0&#x02013;6.0)</td><td>7.0 (6.0&#x02013;9.0)</td><td>&#x0003c;0.001</td></tr><tr><td>MELD (points)</td><td>9.0 (8.0&#x02013;13.0)</td><td>14.0 (10.0&#x02013;17.0)</td><td>&#x0003c;0.001</td></tr><tr><td>Bilirubin (mg/dl)</td><td>0.9 (0.7&#x02013;1.8)</td><td>1.5 (0.8&#x02013;2.6)</td><td>&#x0003c;0.001</td></tr><tr><td>Albumin (g/dl)<hr/></td><td>39.0 (36.1&#x02013;41.8)<hr/></td><td>35.3 (31.1&#x02013;38.7)<hr/></td><td>&#x0003c;0.001<hr/></td></tr><tr><td>IL-6<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref> (ng/dl)</td><td>5.6 (3.4&#x02013;9.5)</td><td>11.5 (7.1&#x02013;20.7)</td><td>&#x0003c;0.001</td></tr><tr><td>CRP (mg/dl)</td><td>0.2 (0.1&#x02013;0.4)</td><td>0.4 (0.1&#x02013;0.8)</td><td>&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>The groups were compared via Mann-Whitney <italic>U</italic> test. cACLD, compensated advanced chronic liver disease; CRP, C-reactive protein; CTP, Child&#x02013;Turcotte&#x02013;Pugh; dACLD, decompensated advanced chronic liver disease; fT3, free triiodothyronine; fT4, free thyroxin; MELD, model for end-stage liver disease; TSH, thyroid stimulating hormone.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnlowast"><label>&#x02217;</label><p id="ntpara0015">Available in 286 patients (cACLD, n&#x000a0;= 124; dACLD, n&#x000a0;= 162).</p></fn></table-wrap-foot></table-wrap></p><p id="p0105">Moreover, IL-6 (from 4.6&#x000a0;ng/dl [pACLD] to 13.5&#x000a0;ng/dl [S5]; <italic>p</italic>&#x000a0;&#x0003c;0.001) and CRP (from 0.2&#x000a0;mg/dl [pACLD] to 0.4&#x000a0;mg/dl [S5]; <italic>p</italic>&#x000a0;&#x0003c;0.001), as well as parameters of hepatic dysfunction (see <xref rid="appsec1" ref-type="sec">Table&#x000a0;S1</xref>), significantly increased with progressive clinical ACLD stage.</p><p id="p0110">Interestingly, as detailed in <xref rid="appsec1" ref-type="sec">Table&#x000a0;S2</xref>, TSH and fT3 did not differ between distinct BMI strata in both patients with cACLD and patients with dACLD.</p></sec><sec id="sec3.3"><title>Correlations of parameters of the pituitary&#x02013;adrenal axis, liver function, and systemic inflammation</title><p id="p0115">Levels fT3 did not correlate with fT4 (&#x003c1;&#x000a0;= 0.000; <italic>p</italic>&#x000a0;= 0.998; <xref rid="fig3" ref-type="fig">Fig.&#x000a0;3</xref>) and only weakly correlated with TSH (&#x003c1;&#x000a0;= -0.152; <italic>p</italic>&#x000a0;= 0.009). Similarly, fT4 showed no correlation with TSH (&#x003c1;&#x000a0;= -0.109; <italic>p</italic>&#x000a0;= 0.061). Interestingly, there were moderate correlations between fT3 and parameters of liver dysfunction (MELD: &#x003c1;&#x000a0;= -0.448; <italic>p</italic> &#x0003c;0.001; and albumin: &#x003c1;&#x000a0;= 0.434; <italic>p</italic> &#x0003c;0.001) and systemic inflammation (IL-6: &#x003c1;&#x000a0;= -0.496; <italic>p</italic> &#x0003c;0.001; and CRP: &#x003c1;&#x000a0;= -0.356; <italic>p</italic> &#x0003c;0.001). Furthermore, fT3 correlated with parameters of PH (HVPG: &#x003c1;&#x000a0;= -0.300; <italic>p</italic> &#x0003c;0.001), endothelial dysfunction (von Willebrand factor antigen [VWF]: &#x003c1;&#x000a0;= -0.357; <italic>p</italic> &#x0003c;0.001), and hyperdynamic circulation (pro-brain-type natriuretic peptide [proBNP]: &#x003c1;&#x000a0;= -0.385; <italic>p</italic> &#x0003c;0.001). By contrast, fT4 and TSH showed no or merely weak correlations with these parameters (see <xref rid="fig3" ref-type="fig">Fig.&#x000a0;3</xref> and <xref rid="appsec1" ref-type="sec">Table&#x000a0;S3</xref>).<fig id="fig3"><label>Fig.&#x000a0;3</label><caption><p>Correlations of fT3, fT4, and TSH with parameters of the pituitary&#x02013;thyroid axis, liver dysfunction, portal hypertension, endothelial dysfunction, hyperdynamic circulation, and systemic inflammation.</p><p>Correlations are indicated as Spearman's correlation coefficient. Asterisks signify significant correlations: &#x02217;<italic>p</italic> &#x0003c;0.050; &#x02217;&#x02217;<italic>p</italic> &#x0003c;0.001. CRP, C-reactive protein; fT3, free triiodothyronine; fT4, free thyroxin; HVPG, hepatic venous pressure gradient; MELD, model for end-stage liver disease; proBNP, pro-brain-type natriuretic peptide; TSH, thyroid-stimulating hormone; VWF, von Willebrand factor antigen.</p></caption><graphic xlink:href="gr3"/></fig></p><p id="p0120">In multivariate linear regression analysis, fT3 was independently linked to CRP (per mg/dl; aB -0.17; <italic>p</italic>&#x000a0;= 0.048; <xref rid="appsec1" ref-type="sec">Table&#x000a0;S4</xref>), CTP score (per point; aB -0.15; <italic>p</italic> &#x0003c;0.001), and age (per 10 years; aB -0.11; <italic>p</italic> &#x0003c;0.001), whereas the only parameter independently associated with TSH was CRP (per mg/dl; aB 0.45; <italic>p</italic>&#x000a0;= 0.046). In addition, we demonstrated a significant relation of fT3 and systemic inflammation within the subgroup of patients with dACLD on linear regression analysis (<xref rid="appsec1" ref-type="sec">Table&#x000a0;S5</xref>).</p></sec><sec id="sec3.4"><title>FU and clinical outcomes</title><p id="p0125">The median FU period was 419.0 days. Overall, 25.3% of patients (n&#x000a0;= 75) experienced at least one (further) decompensation event. Details on the rates of different decompensation events are given in <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>. Ten patients (3.4%) developed HCC during FU. TIPS implantation was conducted in 5.7% (n&#x000a0;= 17) of patients, and 19 patients (6.4%) underwent LT. Furthermore, 11.1% (n&#x000a0;= 33) of patients died with 20 of these deaths (60.6%) being attributed to liver disease.<table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>Follow-up, TIPS implantation, and clinical outcomes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clinical outcome</th><th>All patients (N&#x000a0;= 297)</th></tr></thead><tbody><tr><td>Follow-up time (days), median (IQR)<hr/></td><td>419.0 (156.5&#x02013;797.5)<hr/></td></tr><tr><td>Decompensation event, n (%)</td><td>75 (25.3)</td></tr><tr><td>Ascitic complication, n (%)</td><td>43 (14.5)</td></tr><tr><td>Variceal bleeding, n (%)</td><td>13 (4.4)</td></tr><tr><td>Hepatic encephalopathy, n (%)</td><td>39 (13.1)</td></tr><tr><td>ACLF, n (%)<hr/></td><td>26 (8.8)<hr/></td></tr><tr><td>Bacterial infections<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref>, n (%)</td><td>38 (12.8)</td></tr><tr><td>SBP, n (%)</td><td>8 (2.7)</td></tr><tr><td>Acute kidney injury<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref>, n (%)<hr/></td><td>24 (8.1)<hr/></td></tr><tr><td>HCC, n (%)</td><td>10 (3.4)</td></tr><tr><td>TIPS implantation, n (%)</td><td>17 (5.7)</td></tr><tr><td>Liver transplantation, n (%)</td><td>19 (6.4)</td></tr><tr><td>Death, n (%)</td><td>33 (11.1)</td></tr><tr><td>Liver-related death, n (%)</td><td>20 (6.7)</td></tr></tbody></table><table-wrap-foot><fn><p>ACLF, acute-on-chronic liver failure; HCC, hepatocellular carcinoma; SBP, spontaneous bacterial peritonitis; TIPS, transjugular intrahepatic portosystemic shunt.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnlowast"><label>&#x02217;</label><p id="ntpara0020">Information on bacterial infections and acute kidney injury is available in n&#x000a0;= 287 patients.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.5"><title>Impact of TSH, fT4, and fT3 on clinical outcomes in patients with ACLD</title><p id="p0130"><xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref> shows the impact of fT3 on the risk of (further) decompensation, ACLF, and liver-related death. After adjustment for relevant cofactors, lower fT3 was associated with higher risk of (further) decompensation (adjusted subdistribution hazard ratio [asHR] 0.60; 95% CI 0.37&#x02013;0.97; <italic>p</italic>&#x000a0;= 0.037), ACLF (asHR 0.19; 95% CI 0.08&#x02013;0.49; <italic>p</italic> &#x0003c;0.001), and liver-related death (asHR 0.14; 95% CI 0.04&#x02013;0.51; <italic>p</italic>&#x000a0;= 0.003). TSH (see <xref rid="appsec1" ref-type="sec">Table&#x000a0;S6</xref>) and fT4 (see <xref rid="appsec1" ref-type="sec">Table&#x000a0;S7</xref>) were not linked to adverse outcomes in multivariate analyses.<table-wrap position="float" id="tbl4"><label>Table&#x000a0;4</label><caption><p>Impact of fT3 on the risk of (i) decompensation or further decompensation, (ii) ACLF, and (iii) liver-related death.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Parameter</th><th colspan="3">Univariate (unadjusted) analysis<hr/></th><th colspan="3">Multivariate (adjusted) analysis<hr/></th></tr><tr><th>sHR</th><th>95% CI</th><th><italic>p</italic> value</th><th>asHR</th><th>95% CI</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="7"><bold>(i) Outcome: (further) decompensation</bold></td></tr><tr><td>fT3 (pg/ml)</td><td>0.48</td><td>0.32&#x02013;0.72</td><td><bold>&#x0003c;0.001</bold></td><td>0.60</td><td>0.37&#x02013;0.97</td><td><bold>0.037</bold></td></tr><tr><td>Age (10 years)</td><td>0.98</td><td>0.81&#x02013;1.19</td><td>0.840</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td></tr><tr><td>Sex (male)</td><td>0.90</td><td>0.54&#x02013;1.51</td><td>0.690</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>0.99</td><td>0.93&#x02013;1.05</td><td>0.720</td><td>1.03</td><td>0.96&#x02013;1.10</td><td>0.400</td></tr><tr><td>Child&#x02013;Turcotte&#x02013;Pugh score (points)</td><td>1.26</td><td>1.13&#x02013;1.39</td><td><bold>&#x0003c;0.001</bold></td><td>1.12</td><td>0.96&#x02013;1.30</td><td>0.160</td></tr><tr><td>Creatinine (mg/dl)</td><td>0.83</td><td>0.60&#x02013;1.16</td><td>0.280</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td></tr><tr><td>Sodium (mmol/L)</td><td>0.93</td><td>0.89&#x02013;0.98</td><td><bold>0.009</bold></td><td>1.01</td><td>0.94&#x02013;1.09</td><td>0.800</td></tr><tr><td>HVPG (mmHg)</td><td>1.10</td><td>1.07&#x02013;1.14</td><td><bold>&#x0003c;0.001</bold></td><td>1.09</td><td>1.05&#x02013;1.14</td><td><bold>&#x0003c;0.001</bold></td></tr><tr><td>C-reactive protein (mg/dl)</td><td>1.49</td><td>1.01&#x02013;2.19</td><td><bold>0.042</bold></td><td>0.78</td><td>0.47&#x02013;1.30</td><td>0.340</td></tr><tr><td colspan="7"><bold>(ii) Outcome: ACLF</bold></td></tr><tr><td>fT3 (pg/ml)</td><td>0.15</td><td>0.07&#x02013;0.33</td><td><bold>&#x0003c;0.001</bold></td><td>0.19</td><td>0.08&#x02013;0.49</td><td><bold>&#x0003c;0.001</bold></td></tr><tr><td>Age (10 years)</td><td>1.27</td><td>0.83&#x02013;1.94</td><td>0.270</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td></tr><tr><td>Sex (male)</td><td>1.02</td><td>0.39&#x02013;2.65</td><td>0.970</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>0.95</td><td>0.78&#x02013;1.15</td><td>0.610</td><td>1.02</td><td>0.94&#x02013;1.11</td><td>0.630</td></tr><tr><td>Child&#x02013;Turcotte&#x02013;Pugh score (points)</td><td>1.54</td><td>1.28&#x02013;1.86</td><td><bold>&#x0003c;0.001</bold></td><td>1.16</td><td>0.88&#x02013;1.52</td><td>0.300</td></tr><tr><td>Creatinine (mg/dl)</td><td>1.23</td><td>1.06&#x02013;1.43</td><td><bold>0.007</bold></td><td>0.87</td><td>0.68&#x02013;1.12</td><td>0.290</td></tr><tr><td>Sodium (mmol/L)</td><td>0.85</td><td>0.79&#x02013;0.92</td><td><bold>&#x0003c;0.001</bold></td><td>0.90</td><td>0.79&#x02013;1.01</td><td>0.077</td></tr><tr><td>HVPG (mmHg)</td><td>1.07</td><td>0.92&#x02013;1.25</td><td>0.390</td><td>1.11</td><td>1.02&#x02013;1.20</td><td><bold>0.011</bold></td></tr><tr><td>C-reactive protein (mg/dl)</td><td>2.21</td><td>1.21&#x02013;4.02</td><td><bold>0.009</bold></td><td>0.82</td><td>0.39&#x02013;1.73</td><td>0.610</td></tr><tr><td colspan="7"><bold>(iii) Outcome: Liver-related death</bold></td></tr><tr><td>fT3 (pg/ml)</td><td>0.11</td><td>0.04&#x02013;0.30</td><td><bold>&#x0003c;0.001</bold></td><td>0.14</td><td>0.04&#x02013;0.51</td><td><bold>0.003</bold></td></tr><tr><td>Age (10 years)</td><td>1.22</td><td>0.75&#x02013;2.01</td><td>0.420</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td></tr><tr><td>Sex (male)</td><td>0.78</td><td>0.27&#x02013;2.30</td><td>0.650</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>0.91</td><td>0.79&#x02013;1.05</td><td>0.210</td><td>1.02</td><td>0.88&#x02013;1.18</td><td>0.780</td></tr><tr><td>Child&#x02013;Turcotte&#x02013;Pugh score (points)</td><td>1.63</td><td>1.26&#x02013;2.09</td><td><bold>&#x0003c;0.001</bold></td><td>1.12</td><td>0.75&#x02013;1.66</td><td>0.580</td></tr><tr><td>Creatinine (mg/dl)</td><td>1.03</td><td>0.86&#x02013;1.22</td><td>0.780</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td></tr><tr><td>Sodium (mmol/L)</td><td>0.83</td><td>0.75&#x02013;0.91</td><td><bold>&#x0003c;0.001</bold></td><td>0.89</td><td>0.75&#x02013;1.05</td><td>0.150</td></tr><tr><td>HVPG (mmHg)</td><td>1.15</td><td>1.07&#x02013;1.24</td><td><bold>&#x0003c;0.001</bold></td><td>1.13</td><td>1.03&#x02013;1.25</td><td><bold>0.013</bold></td></tr><tr><td>C-reactive protein (mg/dl)</td><td>2.21</td><td>1.12&#x02013;4.35</td><td><bold>0.022</bold></td><td>0.75</td><td>0.28&#x02013;2.02</td><td>0.570</td></tr></tbody></table><table-wrap-foot><fn id="tspara0045"><p>Univariate and multivariate Fine and Grey competing risk regression models are shown. Etiological cure, hepatocellular carcinoma, liver transplantation, and non-liver-related death were considered as competing risks. <italic>P</italic> values in bold denote statistical significance.</p></fn><fn id="tspara0050"><p>ACLF, acute-on-chronic liver failure; asHR, adjusted sHR; fT3, free triiodothyronine; HVPG, hepatic venous pressure gradient; sHR, subdistribution hazard ratio.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.6"><title>Low fT3 for risk stratification in patients with ACLD</title><p id="p0135">A detailed comparison of characteristics of patients with and without low fT3 is provided in <xref rid="appsec1" ref-type="sec">Table&#x000a0;S8</xref>. Patients with low fT3 more frequently developed (further) decompensation (36.8% <italic>vs</italic>. 23.6% [non-low fT3]; <italic>p</italic>&#x000a0;= 0.078; <xref rid="appsec1" ref-type="sec">Table&#x000a0;S9</xref>), ACLF (28.9% <italic>vs</italic>. 5.8% [non-low fT3]; <italic>p</italic> &#x0003c;0.001), and liver-related death (28.9% <italic>vs</italic>. 3.5% [non-low fT3]; <italic>p</italic> &#x0003c;0.001). Moreover, the rate of SBP was higher in the low fT3 group (7.9% <italic>vs</italic>. 1.9% [non-low fT3]; <italic>p</italic>&#x000a0;= 0.034).</p><p id="p0140">Patients with low fT3 exhibited a higher cumulative incidence of (further) decompensation (<italic>p</italic>&#x000a0;= 0.039; <xref rid="appsec1" ref-type="sec">Table&#x000a0;S10</xref>), ACLF (<italic>p</italic>&#x000a0;&#x0003c;0.001), and liver-related death (<italic>p</italic> &#x0003c;0.001) (<xref rid="fig4" ref-type="fig">Fig.&#x000a0;4</xref>). The cumulative incidence of liver-related death was significantly higher among patients with low fT3 both at 1 year (18.6% [low fT3] <italic>vs</italic>. 1.8% [non-low fT3]) and at 2 years of FU (28.4% [low fT3] <italic>vs</italic>. 2.7% [non-low fT3]; <italic>p</italic> &#x0003c;0.001).<fig id="fig4"><label>Fig.&#x000a0;4</label><caption><p>Cumulative incidence of first/further hepatic decompensation, ACLF, and liver-related death within 2 years of follow-up stratified by fT3 levels.</p><p>Etiological cure, hepatocellular carcinoma, liver transplantation, and non-liver-related death were considered as competing risks. Cumulative incidences were compared using Gray&#x02019;s test. ACLF, acute-on-chronic liver failure; fT3, free triiodothyronine.</p></caption><graphic xlink:href="gr4"/></fig></p><p id="p0145">After adjustment for clinically relevant cofactors, low fT3 was independently associated with higher risk of ACLF (asHR 4.58; 95% CI 1.77&#x02013;11.87; <italic>p</italic>&#x000a0;= 0.002; <xref rid="appsec1" ref-type="sec">Table&#x000a0;S11</xref>) and liver-related death (asHR 6.80; 95% CI 2.05&#x02013;22.56; <italic>p</italic>&#x000a0;= 0.002). In multivariate analysis, low fT3 was not linked to (further) decompensation (asHR 1.33; 95% CI 0.58&#x02013;3.05; <italic>p</italic>&#x000a0;= 0.510).</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0150">In this study, we demonstrated that the pituitary&#x02013;thyroid signaling axis becomes gradually impaired with progressing stages of ACLD and that low fT3 levels are of critical prognostic value in a large well-characterized cohort of patients with ACLD. Specifically, lower fT3 levels across the distinct clinical ACLD substages were paralleled by increases in TSH, whereas fT4 remains mostly unchanged. Importantly, fT3 and TSH were independently linked to CRP, suggesting a key role of systemic inflammation in the dysregulation of thyroid hormone signaling in ACLD. Furthermore, lower fT3 levels correlated with parameters of liver dysfunction, PH, endothelial dysfunction, and hyperdynamic circulation, indicating a potential role of altered thyroid signaling in ACLD progression. Finally, we demonstrated that fT3 &#x02013; as both a continuous variable and dichotomized variable &#x02013; confers important prognostic value, as it was an independent predictor of ACLF development and liver-related mortality.</p><p id="p0155">It has long been known that thyroid hormone dysregulation occurs in liver cirrhosis<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> with abnormalities of thyroid hormones described in 13&#x02013;61% of patients.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Typically, patients with ACLD exhibit decreased total T3, fT3, and fT4, as well as increased reverse T3 compared with healthy individuals, while usually maintaining normal levels of TSH.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Accordingly, in our study the majority of patients with ACLD showed euthyroid function. Furthermore, previous studies have shown that lower fT3 is associated with hepatic dysfunction (<italic>i.e</italic>. higher Child&#x02013;Pugh scores),<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> whereas there were no differences in the levels of fT4 between patients with compensated and decompensated cirrhosis.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref></p><p id="p0160">This is in line with our data, demonstrating that fT3 significantly declines with progressive clinical stage of ACLD, along with increasing TSH levels with progressive clinical ACLD stage. Interestingly, the prevalence of elevated TSH was low (3.0% of patients) and did not differ between different stages of ACLD, and median levels of fT4 were virtually identical in different substages of ACLD, indicating that patients with dACLD, despite exhibiting progressively lower fT3 seem to mostly remain in a euthyroid state.</p><p id="p0165">These thyroid hormone alterations correspond to a non-thyroidal illness syndrome or euthyroid sick syndrome, which can be described to occur in patients with severe or chronic illness.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> Different underlying pathogenetic mechanisms have been proposed, including a downregulation of type 1 deiodinase, hampering the conversion of T4 to T3, reduced hepatic clearance of reverse T3, or changes in the concentration of thyroid hormone binding proteins in patients with ACLD.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Notably, we demonstrate a strong linear correlation between lower fT3 and higher CRP, which strongly suggests a critical contribution of systemic inflammation to lowered fT3 levels with progressive ACLD severity.</p><p id="p0170">Generally, patients with ACLD &#x02013; particularly those with dACLD &#x02013; exhibit increased levels of systemic inflammation<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> that is mechanistically caused by intestinal dysbiosis and bacterial translocation.<xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref> It has been demonstrated that chronic inflammation leads to altered transport and metabolism of thyroid hormones.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> Moreover, systemic inflammation has also been linked to a suppression of the pituitary&#x02013;adrenal axis in ACLD,<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> and indeed, CRP was the only parameter independently linked to TSH in our study population. Thus, chronic inflammation in patients with advanced stages of ACLD may contribute to the dysregulation of thyroid hormone homeostasis both by impairment of the pituitary&#x02013;thyroid axis and by influencing hormone transport and metabolism.</p><p id="p0175">Although a detrimental effect of low fT3 (<italic>i.e.</italic> fT3 &#x0003c;LLN) on survival in patients with cirrhosis has been previously described,<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> our study adds to this finding by demonstrating that lower fT3 levels &#x02013; even when remaining in the normal range &#x02013; when considering them as continuous, and not only as a binary parameter, are strongly linked to development of ACLF and liver-related death. On univariate analyses, lower fT3 levels also predicted (further) decompensation in patients with ACLD, whereas TSH and fT4 did not show any correlations with clinical outcomes. Mechanistically, fT3 showed a correlation to parameters of hepatic dysfunction (<italic>i.e</italic>. MELD and albumin), PH (<italic>i.e.</italic> HVPG), endothelial dysfunction (<italic>i.e.</italic> VWF<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref>), and hyperdynamic circulation (<italic>i.e.</italic> proBNP<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref>), suggesting a role of fT3 in ACLD progression. At this point, further mechanistic studies are required to decipher the impact of fT3 hormones on ACLD progression and particularly on immune dysfunction (cirrhosis-associated immune dysfunction).</p><p id="p0180">Our study also has limitations. Firstly, we did not assess levels of thyroglobulin or reverse T3 and can thus not comment on their role in altered thyroid hormone signaling in ACLD. Thyroglobulin and reverse T3 were previously reported to be elevated in liver cirrhosis.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>38</sup></xref> Secondly, the retrospective design and the long study period represent another limitation. Importantly, we started to systematically assess fT4 and fT3 in April 2018 in patients who were prospectively included and followed up in the VICIS study, which includes 96.4% (n&#x000a0;= 287/297) of patients in this study. By assessing thyroid hormones in consecutive patients undergoing HVPG measurement, we can largely exclude selection bias. Thirdly, we could not measure intrahepatic deiodinase expression/activity and systemic T3/T4-binding globulin levels to assess potential loco-hepatic hypothyroidism and dysregulation of the thyroid hormone metabolism in ACLD, respectively. Moreover, we did not assess anti-thyroglobulin or anti-thyroid peroxidase antibodies. However, no patient with autoimmune thyroid disease or intake of antithyroid medication was included in our study. Furthermore, only 11.8% of patients included in this study had MASH as primary liver disease etiology. Further research is required to explore the specific impact of thyroid hormone imbalance in patients with metabolic dysfunction-associated steatotic liver disease and MASH. Finally, we did not assess nutritional status or sarcopenia, which may influence fT3 levels.</p><p id="p0185">In conclusion, our large observational study showed a significant increase in TSH and decline of fT3 levels with progressive&#x000a0;clinical stage of ACLD. Mechanistically, lower fT3 seems to be&#x000a0;linked to liver dysfunction, PH, endothelial dysfunction, and&#x000a0;hyperdynamic circulation. Interestingly, both lower fT3 and&#x000a0;higher TSH were associated with biomarkers of systemic inflammation.</p><p id="p0190">Finally, and clinically most relevant, lower fT3 levels were independent predictors of hepatic decompensation, ACLF, and liver-related mortality. Based on our study results, regular monitoring of thyroid hormones &#x02013; particularly fT3 &#x02013; in patients with ACLD is warranted. Further studies are required to determine whether specific therapeutic interventions correcting thyroid hormone imbalances may benefit patients with ACLD.</p></sec><sec id="sec5"><title>Financial support</title><p id="p0195">No specific funding was received for this study.</p></sec><sec id="sec7"><title>Authors&#x02019; contributions</title><p id="p0210">Contributed to research design: LH, TR. Contributed to data acquisition: LH, BSim, MJ, DB, RP, BSch, LB, GS, MM, TR. Contributed to data analysis: LH, PW, MM, TR. Contributed to data interpretation: all authors. Drafted the manuscript: LH, TR. Critically revised the manuscript: all other authors.</p></sec><sec sec-type="data-availability" id="sec8"><title>Data availability statement</title><p id="p0215">The data are available upon reasonable request to the corresponding author.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p id="p0200">The authors have nothing to disclose regarding the work under consideration for publication. Conflicts of interest outside the submitted work: LH, MJ, PW, LB, GS, MS, RM, and VD have nothing to disclose. BSim received travel support from AbbVie and Gilead. DJMB received speaker fees from AbbVie and Siemens, grant support form Gilead and Siemens, and travel support from AbbVie and Gilead. BSch received travel support from AbbVie, Ipsen, and Gilead. MT served as a speaker and/or consultant and/or advisory board member for Albireo, BiomX, Falk, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Genfit, Gilead, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, and Shire, and received travel support from AbbVie, Falk, Gilead, and Intercept, as well as grants/research support from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and UltraGenyx. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid. MM served as a speaker and/or consultant and/or advisory board member for AbbVie, Collective Acumen, Gilead, Takeda, and W. L. Gore &#x00026; Associates and received travel support from AbbVie and Gilead. TR served as a speaker and/or consultant and/or advisory board member for AbbVie, Bayer, Boehringer Ingelheim, Gilead, Intercept, MSD, Siemens, and W. L. Gore &#x00026; Associates and received grants/research support from AbbVie, Boehringer Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Pliant, Philips, Siemens, and W. L. Gore &#x00026; Associates as well as travel support from AbbVie, Boehringer Ingelheim, Gilead, and Roche.</p><p id="p0205">Please refer to the accompanying ICMJE disclosure forms for further details.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Sepanlou</surname><given-names>S.G.</given-names></name><name><surname>Safiri</surname><given-names>S.</given-names></name><name><surname>Bisignano</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990&#x02013;2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title><source>Lancet Gastroenterol Hepatol</source><volume>5</volume><year>2020</year><fpage>245</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">31981519</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>D'Amico</surname><given-names>G.</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G.</given-names></name><name><surname>Pagliaro</surname><given-names>L.</given-names></name></person-group><article-title>Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies</article-title><source>J&#x000a0;Hepatol</source><volume>44</volume><year>2006</year><fpage>217</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">16298014</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>de Franchis</surname><given-names>R.</given-names></name><name><surname>Bosch</surname><given-names>J.</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Baveno VII &#x02013; renewing consensus in portal hypertension</article-title><source>J&#x000a0;Hepatol</source><volume>76</volume><year>2022</year><fpage>959</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">35120736</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Mandorfer</surname><given-names>M.</given-names></name><name><surname>Aigner</surname><given-names>E.</given-names></name><name><surname>Cejna</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)</article-title><source>Wien Klin Wochenschr</source><volume>135</volume><year>2023</year><fpage>493</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">37358642</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>D.</given-names></name><name><surname>Simbrunner</surname><given-names>B.</given-names></name><name><surname>Jachs</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality</article-title><source>J&#x000a0;Hepatol</source><volume>74</volume><year>2021</year><fpage>819</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">33075344</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>D'Amico</surname><given-names>G.</given-names></name><name><surname>Morabito</surname><given-names>A.</given-names></name><name><surname>D'Amico</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Clinical states of cirrhosis and competing risks</article-title><source>J&#x000a0;Hepatol</source><volume>68</volume><year>2018</year><fpage>563</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">29111320</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Hartl</surname><given-names>L.</given-names></name><name><surname>Jachs</surname><given-names>M.</given-names></name><name><surname>Desbalmes</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes</article-title><source>Hepatol Int</source><volume>15</volume><year>2021</year><fpage>1160</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">34021479</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Jalan</surname><given-names>R.</given-names></name><name><surname>Saliba</surname><given-names>F.</given-names></name><name><surname>Pavesi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure</article-title><source>J&#x000a0;Hepatol</source><volume>61</volume><year>2014</year><fpage>1038</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">24950482</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Balcar</surname><given-names>L.</given-names></name><name><surname>Semmler</surname><given-names>G.</given-names></name><name><surname>Pomej</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure</article-title><source>United Eur Gastroenterol J</source><volume>9</volume><year>2021</year><fpage>427</fpage><lpage>437</lpage></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Moreau</surname><given-names>R.</given-names></name><name><surname>Jalan</surname><given-names>R.</given-names></name><name><surname>Gines</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis</article-title><source>Gastroenterology</source><volume>144</volume><year>2013</year><fpage>1426</fpage><lpage>1437</lpage><comment>1437.e1421&#x02013;9</comment><pub-id pub-id-type="pmid">23474284</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Trebicka</surname><given-names>J.</given-names></name><name><surname>Fernandez</surname><given-names>J.</given-names></name><name><surname>Papp</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology</article-title><source>J&#x000a0;Hepatol</source><volume>73</volume><year>2020</year><fpage>842</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">32673741</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Piantanida</surname><given-names>E.</given-names></name><name><surname>Ippolito</surname><given-names>S.</given-names></name><name><surname>Gallo</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The interplay between thyroid and liver: implications for clinical practice</article-title><source>J&#x000a0;Endocrinol Invest</source><volume>43</volume><year>2020</year><fpage>885</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">32166702</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Targher</surname><given-names>G.</given-names></name><name><surname>Montagnana</surname><given-names>M.</given-names></name><name><surname>Salvagno</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients</article-title><source>Clin Endocrinol (Oxf)</source><volume>68</volume><year>2008</year><fpage>481</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">17941901</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A.</given-names></name><name><surname>Nascimbeni</surname><given-names>F.</given-names></name><name><surname>Lonardo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Association between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis</article-title><source>Thyroid</source><volume>28</volume><year>2018</year><fpage>1270</fpage><lpage>1284</lpage><pub-id pub-id-type="pmid">30084737</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Association of non-alcoholic fatty liver disease with thyroid function: a systematic review and meta-analysis</article-title><source>Dig Liver Dis</source><volume>50</volume><year>2018</year><fpage>1153</fpage><lpage>1162</lpage><pub-id pub-id-type="pmid">30224316</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Ritter</surname><given-names>M.J.</given-names></name><name><surname>Amano</surname><given-names>I.</given-names></name><name><surname>Hollenberg</surname><given-names>A.N.</given-names></name></person-group><article-title>Thyroid hormone signaling and the liver</article-title><source>Hepatology</source><volume>72</volume><year>2020</year><fpage>742</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">32343421</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Borzio</surname><given-names>M.</given-names></name><name><surname>Caldara</surname><given-names>R.</given-names></name><name><surname>Borzio</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Thyroid function tests in chronic liver disease: evidence for multiple abnormalities despite clinical euthyroidism</article-title><source>Gut</source><volume>24</volume><year>1983</year><fpage>631</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">6407905</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Bernardi</surname><given-names>M.</given-names></name><name><surname>De Palma</surname><given-names>R.</given-names></name><name><surname>Trevisani</surname><given-names>F.</given-names></name><etal/></person-group><article-title>&#x0201c;Low T3 syndrome&#x0201d; in cirrhosis: effect of beta-blockade</article-title><source>Am J Gastroenterol</source><volume>84</volume><year>1989</year><fpage>727</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">2787100</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Low-free triiodothyronine is associated with poor prognosis of portal hypertension in cirrhosis</article-title><source>Eur J Gastroenterol Hepatol</source><volume>32</volume><year>2020</year><fpage>1358</fpage><lpage>1363</lpage><pub-id pub-id-type="pmid">31895910</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Reiberger</surname><given-names>T.</given-names></name><name><surname>Schwabl</surname><given-names>P.</given-names></name><name><surname>Trauner</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Measurement of the hepatic venous pressure gradient and transjugular liver biopsy</article-title><source>J&#x000a0;Vis Exp</source><volume>160</volume><year>2020</year><object-id pub-id-type="publisher-id">e58819</object-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Scheiner</surname><given-names>B.</given-names></name><name><surname>Balcar</surname><given-names>L.</given-names></name><name><surname>Paternostro</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease</article-title><source>J&#x000a0;Hepatol</source><volume>75</volume><year>2021</year><fpage>270</fpage><lpage>271</lpage></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Zaccherini</surname><given-names>G.</given-names></name><name><surname>Weiss</surname><given-names>E.</given-names></name><name><surname>Moreau</surname><given-names>R.</given-names></name></person-group><article-title>Acute-on-chronic liver failure: definitions, pathophysiology and principles of treatment</article-title><source>JHEP Rep</source><volume>3</volume><year>2021</year><object-id pub-id-type="publisher-id">100176</object-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Ferlitsch</surname><given-names>A.</given-names></name><name><surname>Bota</surname><given-names>S.</given-names></name><name><surname>Paternostro</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient</article-title><source>Liver Int</source><volume>35</volume><year>2015</year><fpage>2115</fpage><lpage>2120</lpage><pub-id pub-id-type="pmid">25585656</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Schwabl</surname><given-names>P.</given-names></name><name><surname>Bota</surname><given-names>S.</given-names></name><name><surname>Salzl</surname><given-names>P.</given-names></name><etal/></person-group><article-title>New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension</article-title><source>Liver Int</source><volume>35</volume><year>2015</year><fpage>381</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">24953516</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>J.P.</given-names></name><name><surname>Gray</surname><given-names>R.J.</given-names></name></person-group><article-title>A&#x000a0;proportional hazards model for the subdistribution of a competing risk</article-title><source>J&#x000a0;Am Stat Assoc</source><volume>94</volume><year>1999</year><fpage>496</fpage><lpage>509</lpage></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Jachs</surname><given-names>M.</given-names></name><name><surname>Hartl</surname><given-names>L.</given-names></name><name><surname>Schaufler</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes</article-title><source>Gut</source><volume>70</volume><year>2021</year><fpage>1758</fpage><lpage>1767</lpage><pub-id pub-id-type="pmid">33199442</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Punekar</surname><given-names>P.</given-names></name><name><surname>Sharma</surname><given-names>A.K.</given-names></name><name><surname>Jain</surname><given-names>A.</given-names></name></person-group><article-title>A&#x000a0;study of thyroid dysfunction in cirrhosis of liver and correlation with severity of liver disease</article-title><source>Indian J Endocrinol Metab</source><volume>22</volume><year>2018</year><fpage>645</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">30294575</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Vincken</surname><given-names>S.</given-names></name><name><surname>Reynaert</surname><given-names>H.</given-names></name><name><surname>Schiettecatte</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Liver cirrhosis and thyroid function: friend or foe?</article-title><source>Acta Clin Belg</source><volume>72</volume><year>2017</year><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">27553585</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Fliers</surname><given-names>E.</given-names></name><name><surname>Boelen</surname><given-names>A.</given-names></name></person-group><article-title>An update on non-thyroidal illness syndrome</article-title><source>J&#x000a0;Endocrinol Invest</source><volume>44</volume><year>2021</year><fpage>1597</fpage><lpage>1607</lpage><pub-id pub-id-type="pmid">33320308</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Farwell</surname><given-names>A.P.</given-names></name></person-group><article-title>Euthyroid sick syndrome</article-title><source>Compr Physiol</source><volume>6</volume><year>2016</year><fpage>1071</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">27065175</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Simbrunner</surname><given-names>B.</given-names></name><name><surname>Mandorfer</surname><given-names>M.</given-names></name><name><surname>Trauner</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Gut&#x02013;liver axis signaling in portal hypertension</article-title><source>World J Gastroenterol</source><volume>25</volume><year>2019</year><fpage>5897</fpage><lpage>5917</lpage><pub-id pub-id-type="pmid">31660028</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Tranah</surname><given-names>T.H.</given-names></name><name><surname>Edwards</surname><given-names>L.A.</given-names></name><name><surname>Schnabl</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Targeting the gut&#x02013;liver&#x02013;immune axis to treat cirrhosis</article-title><source>Gut</source><volume>70</volume><year>2021</year><fpage>982</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">33060124</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Simbrunner</surname><given-names>B.</given-names></name><name><surname>Caparr&#x000f3;s</surname><given-names>E.</given-names></name><name><surname>Neuwirth</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response</article-title><source>Hepatol Int</source><volume>17</volume><year>2023</year><fpage>1045</fpage><lpage>1056</lpage><pub-id pub-id-type="pmid">36881247</pub-id>
</element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Boelen</surname><given-names>A.</given-names></name><name><surname>van der Spek</surname><given-names>A.H.</given-names></name><name><surname>Bloise</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Tissue thyroid hormone metabolism is differentially regulated during illness in mice</article-title><source>J&#x000a0;Endocrinol</source><volume>233</volume><year>2017</year><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">28130411</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Hartl</surname><given-names>L.</given-names></name><name><surname>Simbrunner</surname><given-names>B.</given-names></name><name><surname>Jachs</surname><given-names>M.</given-names></name><etal/></person-group><article-title>An impaired pituitary-adrenal signaling axis in stable cirrhosis is linked to worse prognosis</article-title><source>JHEP Rep</source><volume>5</volume><year>2023</year><object-id pub-id-type="publisher-id">100789</object-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Hartl</surname><given-names>L.</given-names></name><name><surname>Rumpf</surname><given-names>B.</given-names></name><name><surname>Domenig</surname><given-names>O.</given-names></name><etal/></person-group><article-title>The systemic and hepatic alternative renin-angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation</article-title><source>Sci Rep</source><volume>13</volume><year>2023</year><fpage>953</fpage><pub-id pub-id-type="pmid">36653504</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Mandorfer</surname><given-names>M.</given-names></name><name><surname>Schwabl</surname><given-names>P.</given-names></name><name><surname>Paternostro</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity</article-title><source>Aliment Pharmacol Ther</source><volume>47</volume><year>2018</year><fpage>980</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">29377193</pub-id>
</element-citation></ref><ref id="bib39"><label>38</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Heged&#x000fc;s</surname><given-names>L.</given-names></name><name><surname>Kastrup</surname><given-names>J.</given-names></name><name><surname>Feldt-Rasmussen</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Serum thyroglobulin in acute and chronic liver disease</article-title><source>Clin Endocrinol (Oxf)</source><volume>19</volume><year>1983</year><fpage>231</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">6883738</pub-id>
</element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary data</title><p id="p0220">The following are the supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Multimedia component 2</title><p>:</p></caption><media xlink:href="mmc2.docx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc3"><caption><title>Multimedia component 3</title></caption><media xlink:href="mmc3.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc4"><caption><title>Multimedia component 4</title></caption><media xlink:href="mmc4.pdf"/></supplementary-material></p></sec><fn-group><fn id="d35e971"><p id="ntpara0010y">Author names in bold designate shared co-first authorship</p></fn><fn id="appsec2" fn-type="supplementary-material"><p id="p0225">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhepr.2023.100954" id="intref0020">https://doi.org/10.1016/j.jhepr.2023.100954</ext-link>.</p></fn></fn-group></back></article>
